DR. JUDY LIEBERMAN, MD, PHD
Osteopathic Medicine at Longwood Ave, Boston, MA

License number

Massachusetts 50012

Organization information

See more information about JUDY LIEBERMAN at bizstanding.com

Judy Lieberman MD,PHD

750 Washington St, Boston, MA 02111

Industry:

Internist

Phone:

(617) 636-5345 (Phone)

Judy Lieberman

Professional information

Judy Lieberman, Boston MA

Specialties:

Internist

Address:

200 Longwood Ave, Boston, MA 02115

Education:

Harvard Medical School - Doctor of Medicine
Beth Israel Deaconess Medical Center - Fellowship - Hematology and Oncology (Internal Medicine)
Beth Israel Deaconess Medical Center - Residency - Internal Medicine

Board certifications:

American Board of Internal Medicine Certification in Internal Medicine

Dr. Judy Lieberman, Boston MA - MD (Doctor of Medicine)

Specialties:

Hematology

Address:

200 Longwood Ave STE 255, Boston 02115
(617) 278-3106 (Phone), (617) 278-3134 (Fax)
CBR INST. BIOMEDICAL RESEARCH
200 Longwood Ave STE 446, Boston 02115
(617) 278-3106 (Phone), (617) 278-3134 (Fax)

Certifications:

Hematology, 1992, Internal Medicine, 1984

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
Harvard Medical School
Graduated: 1981
Beth Israel Deaconess Medical Center

Method For Determining The Immunocompetence Of A Mammal And Therapies Related Thereto

US Patent:

6197531, Mar 6, 2001

Filed:

Jan 21, 1998

Appl. No.:

9/009958

Inventors:

Judy Lieberman - Brookline MA

Assignee:

Center For Blood Research, Inc. - Boston MA

International Classification:

G01N 3353

US Classification:

435 724

Abstract:

A method for determining the immunocompetence of a mammal is described. Bodily fluid having T cell receptor complexes from a mammal is provided. Expression of a first component and a second component of the T cell receptor complexes is evaluated. An abnormal ratio of the number of cells expressing the first component as compared to the number of cells expressing the second component indicates altered immunocompetence in the mammal. Also described are methods for monitoring a therapeutic treatment of a disease in a mammal associated with an abnormal level of a T cell receptor complex component, methods for assessing the progression of a disease in a mammal associated with an abnormal level of a T cell receptor complex component, methods for predicting the prognosis of a mammal having a disease associated with an abnormal level of a T cell receptor complex component, methods for determining if a mammal is at risk for AIDS, methods for evaluating an agent for use in treating HIV infection, and methods for treating HIV infection in a mammal. Pharmaceutical compositions and kits are also provided.

Inhibition Of Gene Expression Using Rna Interfering Agents

US Patent:

7696179, Apr 13, 2010

Filed:

Oct 29, 2003

Appl. No.:

10/533621

Inventors:

Judy Lieberman - Brookline MA, US
Manjunath Narasimhaswamy - Roslindale MA, US
Erwei Song - Guangzhou, CN
Sang-Kyung Lee - Seoul, KR
Premlata Shankar - Roslindale MA, US

Assignee:

Immune Disease Institute, Inc. - Boston MA

International Classification:

A01N 63/00, A61K 48/00

US Classification:

514 44, 424 932, 435455, 514 55

Abstract:

The present invention is based, at least in part, on the discovery of compositions and methods for the treatment and prevention of infectious diseases or disorders, e. g. , HIV infection, AIDS, and AIDS-related diseases. In particular, the present invention pertains to methods of modulating cellular gene expression or protein activity, e. g. , CCR5, gene expression or protein activity and/or gene expression or protein activity of a gene or sequence of an infectious agent, in order to treat or prevent infectious diseases or disorders, HIV infection, AIDS, or an AIDS-related disease or disorder. In one embodiment the combination of an RNA interfering agent targeting a cellular gene in combination with an RNA interfering agent targeting a gene or sequence of an infectious agent results in prolonged prevention of infection by an infectious agent. The present invention is based on the identification of novel RNA interference agents, e. g. , siRNA molecules, which target cellular genes, e. g.

Compositions And Methods For Inhibition Of Retroviruses

US Patent:

2011014, Jun 16, 2011

Filed:

May 18, 2009

Appl. No.:

12/992797

Inventors:

Nan Yan - Boston MA, US
Alan Engelman - Brookline MA, US
Judy Lieberman - Brookline MA, US

Assignee:

IMMUNE DISEASE INSTITUTE, INC. - Boston MA
DANA-FARBER CANCER INSTITUTE, INC. - Boston MA

International Classification:

A61K 39/42, C12Q 1/68, C12N 5/02, A61K 38/00, A61K 31/7088, A61P 31/18

US Classification:

4241591, 435 612, 435375, 514 38, 514 44 A

Abstract:

Described herein are methods and compositions for the inhibition of retroviral integration and replication. The methods and compositions inhibit the activity of one or more components of the SET complex or base excision repair enzymes and induce autointegration of retroviral double-stranded nucleic acid.

Sirna Microbicides For Preventing And Treating Diseases

US Patent:

7943589, May 17, 2011

Filed:

Jun 5, 2006

Appl. No.:

11/916334

Inventors:

Judy Lieberman - Brookline MA, US
Deborah Palliser - Cambridge MA, US
David Knipe - Auburndale MA, US

Assignee:

President and Fellows of Harvard College - Cambridge MA
Immune Disease Institute, Inc. - Boston MA

International Classification:

A61K 31/70, C07H 21/04, C07H 21/02, C12Q 1/68

US Classification:

514 44A, 536 231, 536 241, 536 245, 435 6, 435375

Abstract:

The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.

Therapeutic And Diagnostic Strategies

US Patent:

2012005, Mar 8, 2012

Filed:

Sep 18, 2009

Appl. No.:

13/063155

Inventors:

Judy Lieberman - Brookline MA, US
Ashish Lal - Brookline MA, US
Dipanjan Chowdhury - Chestnut Hill MA, US

Assignee:

IMMUNE DISEASE INSTITUTE, INC. - Boston MA

International Classification:

A61K 31/7105, A61P 37/00, A61P 37/06, C12N 5/071, A61P 35/00

US Classification:

514 44 A, 435375

Abstract:

The present invention encompasses the finding that microRNAs (miRNAs) regulate certain key proteins involved in DNA repair. In some embodiments, a miRNA suppresses levels and/or activity of one or more DNA repair proteins. In some such embodiments, such suppression renders cells hypersensitive to certain DNA damage agents (e.g., γ-irradiation and genotoxic drugs, among others). The present invention provides various reagents and methods associated with these findings including, among other things, strategies for treating cell proliferative disorders, certain diagnostic systems, etc.

Method Of Delivering Rna Interference And Uses Thereof

US Patent:

8168601, May 1, 2012

Filed:

Aug 15, 2005

Appl. No.:

11/659386

Inventors:

Judy Lieberman - Brookline MA, US
Erwei Song - Guangzhou, CN

Assignee:

Immune Disease Institute, Inc. - Boston MA

International Classification:

A61K 48/00, C07H 21/02, C07H 21/04, C07K 16/00

US Classification:

514 44, 536 231, 536 245, 5303871

Abstract:

The invention provides a method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a fusion protein, the fusion protein comprising (1) a targeting moiety, which will specifically binds to a site on a target cell, and (2) a binding moiety, which will bind to the double stranded RNA, wherein the double stranded RNA segment initiates RNA interference in the cell.